AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023.
In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.